TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 12/3030% below fair value
$1.82−0.03 (-1.62%)
Close on Nov 12, 2026Market cap $21.07MP/E –Yield –
TherapeuticsMD total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
TherapeuticsMD's total debt was $93.60M at Sep 30, 2022. For fiscal 2021 it was $188.27M, down 20.8% from the year before. The highest annual figure on record is $237.70M in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $188.27M | -20.8% |
| FY2020 | Dec 31, 2020 | $237.70M | +22.1% |
| FY2019 | Dec 31, 2019 | $194.63M | +165.2% |
| FY2018 | Dec 31, 2018 | $73.38M | +1944.5% |
| FY2012 | Dec 31, 2012 | $3.59M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2022 | Sep 30, 2022 | $93.60M | -49.9% |
| Q2 FY2022 | Jun 30, 2022 | $90.78M | -51.0% |
| Q1 FY2022 | Mar 31, 2022 | $202.86M | +10.3% |
| Q4 FY2021 | Dec 31, 2021 | $188.27M | -20.8% |
| Q3 FY2021 | Sep 30, 2021 | $186.74M | -21.2% |
| Q2 FY2021 | Jun 30, 2021 | $185.26M | -24.0% |
| Q1 FY2021 | Mar 31, 2021 | $183.97M | -24.4% |
| Q4 FY2020 | Dec 31, 2020 | $237.70M | +22.1% |
| Q3 FY2020 | Sep 30, 2020 | $237.05M | +22.0% |
| Q2 FY2020 | Jun 30, 2020 | $243.80M | +25.6% |
| Q1 FY2020 | Mar 31, 2020 | $243.43M | +231.2% |
| Q4 FY2019 | Dec 31, 2019 | $194.63M | +165.2% |
| Q3 FY2019 | Sep 30, 2019 | $194.36M | +165.3% |
| Q2 FY2019 | Jun 30, 2019 | $194.10M | +165.4% |
| Q1 FY2019 | Mar 31, 2019 | $73.50M | – |
| Q4 FY2018 | Dec 31, 2018 | $73.38M | – |
| Q3 FY2018 | Sep 30, 2018 | $73.26M | – |
| Q2 FY2018 | Jun 30, 2018 | $73.14M | – |
See a number that looks wrong?